Monitor Biogen's integration of Amicus' commercial operations and upcoming Q1 earnings call for updated 2026 guidance. The acquisition significantly expands Biogen's rare disease portfolio with two commercial products, potentially driving revenue growth, but increases leverage that will need to be managed.
Price Chart
Executive Summary
Biogen completed its acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction, funding the deal through a $2.8 billion term loan package and previously issued notes. The acquisition adds Fabry and Pompe disease treatments to Biogen's portfolio, strengthening its rare disease focus.
Key Financial Metrics
Key Facts
- Completed acquisition of Amicus Therapeutics for $4.8 billion in all-cash transaction
- Acquired Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease) treatments
- Financed through $2.0 billion Term Loan B, $800 million Term Loan A, and $850 million 2034 Notes
- Existing credit agreement was repaid and terminated
- New senior secured credit facilities have five- to seven-year maturities
Financial Impact
$4.8 billion acquisition funded by $2.8 billion in new term loans and existing capital
Risk Factors
- Integration challenges between the two companies
- Increased debt burden from the acquisition financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179243 |
| Document: d113922d8k.htm | 0001193125-26-179243 |
| Document: d113922dex991.htm | 0001193125-26-179243 |
| Document: d113922dex41.htm | 0001193125-26-179243 |
| Document: 0001193125-26-179243-index-headers.html | 0001193125-26-179243 |
| Document: 0001193125-26-179243-index.html | 0001193125-26-179243 |
| Document: 0001193125-26-179243.txt | 0001193125-26-179243 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $64.45 $63.94 | ▼ −0.79% | ▼ −1.61% | $57.72 (−10.43%) |
Sep 14, 2026 18d ago | 8-K | $66.41 $64.06 | ▼ −3.54% | ▼ −3.65% | $57.72 (−13.08%) |
Sep 1, 2026 4w ago | 8-K | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $57.72 (−10.97%) |
Sep 1, 2026 4w ago | Press Release | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $57.72 (−10.97%) |
Aug 31, 2026 4w ago | 8-K | $65.23 $64.63 | ▼ −0.92% | ▼ −0.78% | $57.72 (−11.51%) |
Aug 18, 2026 6w ago | 8-K | $66.99 $66.12 | ▼ −1.30% | ▼ −1.10% | $57.72 (−13.83%) |
Jun 4, 2026 17w ago | 8-K | $56.77 $55.95 | ▼ −1.44% | ▼ −2.01% | $57.72 (+1.68%) |
Apr 27, 2026 22w ago | 8-K | $53.62 $55.42 | ▲ +3.36% | ▲ +2.96% | $57.72 (+7.65%) |
Apr 21, 2026 23w ago | DEFA14A | $54.16 $53.24 | ▼ −1.71% | ▼ −1.76% | $57.72 (+6.57%) |
Feb 28, 2026 30w ago | Institutional Cluster | $59.71 $60.65 | ▲ +1.57% | ▲ +2.78% | $57.72 (−3.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access